N Engl J Med February 2024 PMID 38381675

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.

Marina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, Ellen K Ritchie, Jason Gotlib, Aaron Gerds, Jeanne Palmer, Kristen Pettit, Uttam K Nath, Abdulraheem Yacoub, Arturo Molina, Samuel R Saks, Nishit B Modi, Frank H Valone, Sarita Khanna

Full text PDF Download social card

Mentions

171

Peak: 69 in Feb 2024

across 5 sources since Feb 2024

Extended reach

2,292,496

potential audience

Total likes

473

Video views

7,220

Mentions per month

Feb 2024 – Sep 2025

Where it's discussed

X / Twitter125 posts
News34 articles
Blogs6 articles
YouTube4 videos
Facebook2 posts

AI synopsis

What people are saying

The discussions reflect a strong interest and support, with phrases like 'promising in controlling hematocrit' and 'effective treatment option' showing enthusiasm. Several posts cite specific trial results such as reductions in phlebotomies and hematocrit, indicating deep engagement and acknowledgment of the study's potential impact on treatment approaches for polycythemia vera.

AgreementModerate agreement

Most discussions express support for the study results, highlighting the positive outcomes and potential of rusfertide in treating polycythemia vera.

InterestHigh interest

The collective tone demonstrates a high level of curiosity and enthusiasm, with many posts emphasizing the significance of the findings.

EngagementHigh engagement

Posts frequently reference specific details like the reduction in phlebotomies and hematocrit levels, showing deep engagement with the research data.

ImpactHigh impact

The widespread sharing, praise, and mention of multiple research groups suggest that the publication could influence clinical practices and future research directions.

Abstract in brief

Polycythemia vera is a chronic blood disorder leading to high red blood cell counts, and rusfertide is a treatment that mimics a hormone controlling iron levels, but its safety and effectiveness in these patients were previously unknown.
The REVIVE trial tested rusfertide in two parts: a 28-week dose-finding phase involving 70 patients, followed by a 12-week phase where participants received either rusfertide or a placebo.
Results showed that patients treated with rusfertide had significantly fewer annual phlebotomies (0.6 vs. 8.7) and a better response rate (60% vs. 17%) compared to the placebo group, along with improvements

Read the full abstract

All mentions

Rusfertide for Managing Erythrocytosis in Polycythemia Vera

This episode discusses diagnosing and managing polycythemia vera with Dr. Gerds. The REVIVE trial shows rusfertide reduces phlebotomies and improves response rates in treating erythrocytosis associated with PV.

Blood Cancer Talks Podcast · Jul 21, 2024 4,841 views

Innovative Treatment for Polycythemia Vera Using Rusfertide

This video discusses the REVIVE trial evaluating rusfertide, a hepcidin mimetic, for controlling erythrocytosis in polycythemia vera. Results show significant reduction in phlebotomies and improved patient response…

DOBBS · Mar 12, 2024 2,283 views

Hepcidin Mimetics and Rusfertide in Polycythemia Vera Treatment

Join Prof Domenico Girelli as he discusses advances in using Hepcidin mimetics like Rusfertide to manage Polycythemia Vera by regulating iron metabolism and erythrocytosis, highlighting recent clinical trial results and…

European Hematology Association · Jun 19, 2024 53 views

Rusfertide: A Promising Treatment for Blood Disorder Polycythemia Vera

A new drug called rusfertide has shown promise in treating polycythemia vera, a rare blood cancer. The clinical trial involving 70 patients demonstrated effective reduction of red blood cell production, lowering…

Finite Future · Mar 13, 2024 44 views

Naveen Pemmaraju, MD

@doctorpemm · X

Sep 6, 2025 · 22 likes · 19,896 followers View post →

Nora Boyer

@noraboyer22 · X

RT @ProtagonistTx: One year ago today, @NEJM published pivotal data from the REVIVE Phase 2 study evaluating a hepcidin mimetic in developm…

Feb 21, 2025 · 1 share · 39 followers View post →

Protagonist Therapeutics

@ProtagonistTx · X

One year ago today, @NEJM published pivotal data from the REVIVE Phase 2 study evaluating a hepcidin mimetic in development for the treatment of polycythemia vera, a myeloproliferative neoplasm affecting ~160,000 patients in the U.S. View the publication: https://t.co/Y6bgnnUyw3

Feb 21, 2025 · 4 likes · 1 share · 354 followers View post →

Shoaib Alam

@ShoaibAlamKhat2 · X

Rusfertide shows promise in controlling hematocrit and reducing phlebotomy needs in polycythemia vera patients, with manageable side effects.

Aug 26, 2024 · 904 followers View post →

Mohamed E. Elrggal

@M_Elraggal · X

RT @FriedmanOded: @kidney_boy Wouldn’t Fe deficiency be erythropoiesis-limiting & therefore desirable here? Isn’t that the rationale of rus…

Aug 26, 2024 · 1 share · 1,698 followers View post →

Oded Friedman, MD MSc

@FriedmanOded · X

@kidney_boy Wouldn’t Fe deficiency be erythropoiesis-limiting & therefore desirable here? Isn’t that the rationale of rusfertide (= hepcidin mimetic) in PV? https://t.co/tGVBsQJ5zF

Aug 23, 2024 · 2 likes · 1 share · 125 followers View post →

Naveen Pemmaraju, MD

@doctorpemm · X

Rusfertide, a #Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera | ⁦@NEJM⁩ | ⁦@MKremyanskaya⁩ ⁦@KuykendallMd⁩ ⁦@doctorpemm⁩ #MPNSM

Jun 17, 2024 · 10 likes · 1 share · 19,896 followers View post →

Krishna Komanduri, MD, FASTCT

@drkomanduri · X

RT @doctorpemm:

Jun 5, 2024 · 31 shares · 12,994 followers View post →

Mercedes Gasior

@mer_501 · X